Exploring Complement Inhibition and Claseprubart in CIDP

Complement inhibition has emerged as a compelling therapeutic strategy in immune-mediated neuromuscular diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP). The complement cascade, when pathologically activated, can amplify inflammation and drive nerve damage through downstream cytokine release and membrane attack complex formation. Traditional CIDP therapies—such as corticosteroids, plasma exchange, and immunoglobulin—broadly suppress immune activity but often fail to precisely target these molecular pathways. As a result, researchers are increasingly investigating selective complement inhibitors that may reduce treatment burden, improve tolerability, and offer sustained disease control without the need for chronic immunosuppression.

In this episode of Advancing CIDP Care, Amit Sachdev, MD, discusses the scientific rationale behind targeting complement activation and provides insight into Dianthus Pharmaceuticals’ ongoing trial of claseprubart, an investigational complement inhibitor for CIDP. He outlines the open-label design of the study, the transition from IVIg to claseprubart, and how this approach enables real-time assessment of disease stability. Dr. Sachdev also explains why complement modulation represents a potential shift in how clinicians approach CIDP treatment—offering a path toward more precise and mechanistically guided care.